|
|
2290 Huntington Drive, Suite 100
San Marino, CA 91108 USA
phone:626.334.5310
fax:626.334.5324
|
|
| Symbol |
VRALE |
| Exchange |
OTC |
| Founded |
0 |
| Employees |
6 |
|
|
| www.viralgenetics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Diagnostic and therapeutic applications of its Thymus Nuclear Protein technology. |
|
| Management |
| Haig Keledjian, CEO, President; Monica Ord, SVP Communications and Corporate Development; Karen Newell, PhD, Advisor; Michael Capizzano, Consultant; Sam Golube, MD, Advisor; Bada Pharisi, Advisor |
| |
|
|
|
|
|
|
|
| Keywords |
| hiv, aids, thymus, diagnostic, therapeutic, HIVAIDS |
|
|
|
| Description |
|
Viral Genetics, Inc. is engaged in the discovery and development of a series of diagnostic and/or therapeutic applications of its Thymus Nuclear Protein technology aimed primarily at the treatment of infectious disease, autoimmune diseases and immunological deficiency. |
|
| Products / Services |
VGV-1
|
|
| Technology / Differentiation |
| The Company's platform technology, Thymus Nuclear Protein (TNP) is a processed extract of mammalian thymus tissue. The Company's lead drug candidate, VGV-1 is a treatment for human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). VGV-1 is a purified extract of mammalian thymus tissue. |
|
| Market / Customers |
The Company is targeting the growing HIV and AIDS therapeutics market. Studies indicate that 70% of patients receiving standard Highly-Active Antiretroviral Therapy (HAART) are resistant to one or more classes of HIV/AIDS drugs and 11-18% are resistant to three classes of antiretrovirals.
|
|
| Status |
| The primary endpoints of its clinical trials have included human CD4+ T cell counts; viral load in plasma using PCR-RNA (polymerase chain reaction), and clinical condition, including standard blood testing and body weight. No significant adverse effects related to VGV-1 have been noted. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
